The $1.7 trillion revenue prescription drug industry has a relatively robust immunity to tariffs. Last Wednesday, when U.S.

Cellular Therapies and IDRx, crossed the $1 billion mark, a notable decrease from the six seen during the same period last ...

Denise Bronner, Ph.D., makes the case for and against acquisitions for rejuvenating Big Pharma pipelines. She explains why outsourcing innovation can be as risky, and costly, as internal discovery.

And while Trump has criticized Ireland for attracting big pharma companies, he’s also suggested he wants to reshore ...

Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are ‘underappreciated.’ ...

Explore the impact of proposed Pharma tariffs on global markets as major stocks tumble. Click for my updated look at selected picks in the health industry.

American big pharma argues the PBS manipulates medicine ... of Universities Australia’s new definition. Two crucial statements are at the heart of their exposition. One is that “Zionism ...

Formerly LBT Innovations, Adelaide-based Clever Culture Systems (ASX:CC5) is now targeting big pharma with its APAS ... aseptically clean environments meaning there’s techniques and practices ...

Biotech Clever Culture Systems has made a significant strategic pivot to target big pharma customers ... which were aseptically clean environments meaning there’s techniques and practices ...

Emily Field, head of European pharma equity research at Barclays ... creating a wholly U.S.-based manufacturing process would mean diverting funds from researching future medicines, and amounts ...